On November 20, 2025, Protagenic Therapeutics, Inc. received a notice from Nasdaq indicating non-compliance with stockholder equity requirements and delayed filings, leading to a determination to delist its securities, though they plan to appeal this decision. The company reported an equity below the required $2,500,000 and has been in the monitoring period due to past compliance issues.